

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/080177

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K38/17 A61K39/395 C07K19/00 C07K16/28 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/068867 A (GENENTECH INC [US]; CHAN ANDREW [US]; GONG QIAN [US]; MARTIN FLAVIUS []) 29 June 2006 (2006-06-29)	1-19
Y	page 3, line 10 - page 5, line 11 page 9, line 34 - page 10, line 6 page 68, line 35 - page 69, line 40; figures 29-31; example 4; sequence 2	4,6
X	WO 2005/005462 A (GENENTECH INC [US]; CHAN ANDREW CHEE-YUEN [US]; GORDON NATHANIEL C [US]) 20 January 2005 (2005-01-20)	1-19
Y	page 3, line 15 - page 9, line 18; example 4; sequence 2	4,6
	----- -/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

17 February 2009

Date of mailing of the international search report

26/02/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2008/080177

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>VUGMEYSTER Y ET AL: "A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys"</p> <p>AMERICAN JOURNAL OF PATHOLOGY 200602 US, vol. 168, no. 2, February 2006 (2006-02), pages 476-489, XP002515030 ISSN: 0002-9440 abstract page 481, left-hand column, paragraph 1 - page 487, right-hand column, last paragraph; figure 3</p> <p>-----</p>	4,6
Y	<p>SILVERMAN G J ET AL: "B cell modulation in rheumatology"</p> <p>CURRENT OPINION IN PHARMACOLOGY - CANCER/IMMUNOMODULATION 200708 GB, vol. 7, no. 4, August 2007 (2007-08), pages 426-433, XP002515031 ISSN: 1471-4892 page 427, right-hand column, paragraph 2 - page 430, left-hand column, paragraph 2; figure 3</p> <p>-----</p>	4,6
A	<p>CHAN A ET AL: "Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease [5]"</p> <p>JOURNAL OF NEUROLOGY 200711 DE, vol. 254, no. 11, November 2007 (2007-11), pages 1604-1606, XP002515032 ISSN: 0340-5354 1432-1459 published online 27-08-2007 the whole document</p> <p>-----</p>	10
A	<p>STUVE O ET AL: "Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis"</p> <p>ARCHIVES OF NEUROLOGY 200510 US, vol. 62, no. 10, October 2005 (2005-10), pages 1620-1623, XP002515033 ISSN: 0003-9942 1538-3687</p> <p>-----</p> <p style="text-align: center;">-/--</p>	10

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2008/080177

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ANOLIK ET AL: "New treatments for SLE: cell-depleting and anti-cytokine therapies"</p> <p>BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL RHEUMATOLOGY, BAILLIERE TINDALL, LONDON, GB, vol. 19, no. 5, 1 October 2005 (2005-10-01), pages 859-878, XP005140891</p> <p>ISSN: 1521-6942</p> <p>the whole document</p> <p>-----</p>	10
A	<p>MUNAFO A ET AL: "Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers"</p> <p>EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 200707 DE, vol. 63, no. 7, July 2007 (2007-07), pages 647-656, XP002515034</p> <p>ISSN: 0031-6970</p> <p>the whole document</p> <p>-----</p>	1
T	<p>DATABASE BIOSIS [Online]</p> <p>BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; September 2008 (2008-09),</p> <p>CARBONATTO MICHELA ET AL: "Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept"</p> <p>XP002515379</p> <p>Database accession no. PREV200800586339</p> <p>abstract</p> <p>& TOXICOLOGICAL SCIENCES, vol. 105, no. 1, September 2008 (2008-09), pages 200-210, ISSN: 1096-6080</p> <p>-----</p>	
T	<p>"InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies"[Online] 2008, pages 1-2, XP002515036</p> <p>INTERNET</p> <p>Retrieved from the Internet:</p> <p>URL: http://www.scientificblogging.com/print/32525></p> <p>& INNEXUS BIOTECHNOLOGY, INC:</p> <p>"Presentation American Association for Cancer Research, San Diego, California"[Online] 2008, pages 1-14, Retrieved from the Internet:</p> <p>URL: http://www.innexusbiotech.com/docs/AACR2008SLIDES.pdf></p> <p>-----</p> <p style="text-align: center;">-/--</p>	

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2008/080177

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>DILILLO DAVID J ET AL: "Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice."</p> <p>JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JAN 2008, vol. 180, no. 1, 1 January 2008 (2008-01-01), pages 361-371, XP002515037 ISSN: 0022-1767</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2008/080177

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006068867 A	29-06-2006	AU 2005319485 A1	29-06-2006
		CA 2590936 A1	29-06-2006
		EP 1831253 A1	12-09-2007
		JP 2008525449 T	17-07-2008
WO 2005005462 A	20-01-2005	AU 2004251679 A1	06-01-2005
		AU 2004256042 A1	20-01-2005
		BR PI0411276 A	01-08-2006
		CA 2526402 A1	20-01-2005
		CA 2528434 A1	06-01-2005
		EP 1631313 A2	08-03-2006
		EP 1629001 A2	01-03-2006
		JP 2007536896 T	20-12-2007
		JP 2007526220 T	13-09-2007
		KR 20060027801 A	28-03-2006
		MX PA05013117 A	17-03-2006
		NZ 543712 A	30-06-2008
		WO 2005000351 A2	06-01-2005